Salvinorin A - Atai Beckley/Nualtis
Alternative Names: INT0054/2020; RLS-01; Salvinorin-ALatest Information Update: 11 Nov 2025
At a glance
- Originator Revixia Life Sciences
- Developer IntelGenx Corp.; Revixia Life Sciences
- Class Behavioural disorder therapies; Mood stabilisers; Neuropsychotherapeutics; Small molecules; Vascular disorder therapies
- Mechanism of Action Opioid kappa receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Treatment-resistant depressive disorder; Unspecified